Loading clinical trials...
Loading clinical trials...
Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation
Conditions
Interventions
autologous tumor cell vaccine
keyhole limpet hemocyanin
+2 more
Locations
3
United States
Arkansas Cancer Research Center
Little Rock, Arkansas, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Medicine Branch
Bethesda, Maryland, United States
Start Date
July 1, 1995
Completion Date
March 1, 2007
Last Updated
March 4, 2024
NCT00644228
NCT00098475
NCT00089011
NCT00002787
NCT01676961
NCT01273766
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions